"Octagon 88 has received confirmation of 1.6 billion billion barrels PIIP," was the headline for the press release dated September 11, 2013. Needless to say, Octagon 88 (OTCBB: OCTX), a small cap oil and natural gas exploration based in Switzerland with assets in the oil-rich Alberta province of Canada, has soared on that and other bullish news. From early July, the stock price for Octagon 88 just about doubled.
As to be expected, the share price has drifted down from the peak after the bullish activity. But long term investors should take note of the resources owned by Octagon 88. Canadian energy assets have drawn "Big Oil" from around the world such as CNOOC (NYSE: CEO) and Chevron (NYSE: CVX). In addition, Suncor Energy (NYSE: SU), a major oil firm based in Canada, has Warren Buffett gobbling up its shares.
Hot Up And Coming Stocks To Buy Right Now: Clovis Oncology Inc (CLVS)
Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.
CO-101 - a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine
CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.
CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor
CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.
The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line treatment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.
CO-338-a PARP Inhibitor
CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!
The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.
Advisors' Opinion:- [By Brian Orelli]
Plenty of data was presented at the American Society for Clinical Oncology meeting over the weekend, causing the first set of ASCO pops, but Clovis Oncology (NASDAQ: CLVS ) looks like the clear winner, more than doubling today as the company presented data on its two cancer drugs rucaparib and CO-1686.
- [By Sean Williams]
Clovis Oncology (NASDAQ: CLVS )
Welcome to fantasyland; population: Clovis shareholders! As my Foolish colleague and health care analyst David Williamson pointed out this week, shareholders enjoyed the best possible perk of biotech ownership Monday based on ASCO data -- a daily double. Clovis shares exploded higher as both its Rucaparib study of solid tumors, and CO-1686 for EGFR-mutant non-small-cell lung cancer, demonstrated strong early-stage results.
Best Warren Buffett Companies To Own In Right Now: Constellium NV (CSTM)
Constellium N.V., formerly Constellium Holdco BV, is a Netherlands-based company, which is engaged in the manufacture of aluminum products and solutions. The Company is a supplier of such sectors as: aerospace, automotive and packaging. Constellium Holdco BV offers plates, sheet and coil, precision casting, cockpit carriers for vehicles, vehicle safety components, profiles, as well as tubes and bars, among others. Its main customers include: Airbus, Boeing, Embraer, Audi, BMW, Citroen, Renault, Mercedes Benz, Jaguar and others. The Company is active domestically and abroad, including North America, Europe and Asia. Advisors' Opinion:- [By Laura Brodbeck]
Thursday
Earnings Expected From: Abercrombie & Fitch (NYSE: ANF), Dollar General (NYSE: DG), Genesco (NYSE: GCO), Constellium NV (NYSE: CSTM) Economic Releases Expected: Japanese retail sales, Japanese industrial production, Japanese unemployment rate, British consumer confidence, U.S. GDP, eurozone consumer confidence, German unemployment rate, Spanish GDPFriday
Best Warren Buffett Companies To Own In Right Now: Potlatch Corporation(PCH)
Potlatch Corporation operates as a real estate investment trust (REIT) that owns and manages timberlands located in Arkansas, Idaho, Minnesota and Wisconsin in the United States. The Resource Management Division manages its timberlands, harvests timber, procures other wood fiber, sells logs and leases land for hunting and other recreational activity. The Real Estate Division develops and sells land parcels, as well as invests in timberlands. The Wood Products Division manufactures lumber, plywood, and particleboard in Arkansas, Idaho, Michigan, and Minnesota. This segment's products are sold to wholesalers primarily for use in home building and other construction activities. Potlatch was founded in 1903 and is headquartered in Spokane, Washington.
Advisors' Opinion:- [By Saibus Research]
WY and the majority of the timber, forest and paper products companies have a track record of unimpressive returns on capital, cyclical revenue and profit trends, heavy use of capital expenditures, and significant environmental regulation. We also think that WY's conversion to a REIT was a mistake. Morningstar Investment Research's Timber, Forest and Paper Products analyst Dan Rohr said it best when he rated WY and its Timber REIT peers Rayonier (RYN), Potlatch (PCH) and Plum Creek (PCL) as not possessing any economic moat. That probably explains why we only have an ancillary exposure to this industry for our proprietary portfolio based on our holdings in Brookfield Infrastructure (BIP) and Cintas (CTAS). Brookfield's Timber segment only accounts for 5% of its Fund Flows from operations and Cintas's document management business is suffering from reduced prices on recycled paper. At least Cintas Document Management only accounts for 8% of Cintas's revenue.
- [By Dan Caplinger]
In Weyerhaeuser's report, watch for the company to discuss any plans for potential buyout activity. With tight supplies, smaller rivals Louisiana-Pacific (NYSE: LPX ) or Potlatch (NASDAQ: PCH ) might make good targets for the larger Weyerhaeuser or Plum Creek to look at for expansion. Even though those companies have seen their shares rise dramatically as well, it might be worth paying up in order to secure long-term assets that could produce strong growth for Weyerhaeuser.
- [By Dividends4Life]
Potlatch Corporation (PCH) operates as a real estate investment trust (REIT) that owns and manages timberlands located in Arkansas, Idaho, Minnesota and Wisconsin. December 6th the company increased its quarterly dividend 13% to $0.35 per share. The dividend is payable December 31, 2013 to stockholders of record on December 17, 2013. The yield based on the new payout is 3.5%.
Best Warren Buffett Companies To Own In Right Now: Uomo Media Inc (UOMO)
UOMO Media Inc., incorporated on June 10, 2004, is in the business of producing, managing, and monetizing music-based intellectual property. The Company provides music publishing, digital music and video, recorded music and production, and talent management services. The Company operates in four divisions: music publishing, recorded music, digital distribution and talent management. The Company has two subsidiaries in Canada, UOMO Productions Inc. and UOMO Music Publishing Inc. In addition, The NE Inc. is a wholly owned subsidiary of UOMO Productions Inc. and UOMO Songs Ltd. is a wholly owned subsidiary of UOMO Music Publishing Inc. As of April 30, 2009, the Company had 22 production customers. The Company�� customers include VideoFact and Universal Music. As of April 30, 2009, the Company was in the development stage.
In the music publishing segment, UOMO Music Publishing Inc. is tasked with creating a catalogue of assets in the form of copyrights. Services include Fund advances, which includes providing advances to individual composers; Administration, which includes registration, tracking, and collection of copyright royalties; Creative, which includes creating copyrights by writing songs, and Licensing, which includes finding opportunities to monetize copyrights by placing songs on recording artists, films, television, video games, commercials.
In the recorded music segment, the Company earns revenue from the ownership of master recordings. UOMO Recorded Music has three functions: catalogue acquisition, talent acquisition for/and production activities and distribution arrangements for projects. UOMO Recorded Music is the record label division of UOMO. Production services also fall under this division.
In the digital distribution segment, the Company has been developing digital music and video Web 2.0 software. In the talent management segment, the Company earns a percentage of gross revenues for all projects it manages. As of April 30, 2009, the Company ! was in the process of developing programming architecture for the new digital music and video portal.
The Company competes with Warner Music Group, EMI, Sony BMG, and Universal Music Group.
Advisors' Opinion:- [By Peter Graham]
Small cap media stocks UOMO Media Inc (OTCMKTS: UOMO), International Display Advertising (OTCMKTS: IDAD) and Media Analytics Corp (OTCBB: MEDA) have been getting some extra media attention lately thanks in part to paid promotions. It should be said that there is nothing wrong with properly disclosed paid promotional or investor relation campaigns for stocks, but they can backfire on unwary investors and traders alike. With that in mind, here is a closer look at along with a reality check for these three small cap media stocks:
Best Warren Buffett Companies To Own In Right Now: Oncothyreon Inc .(ONTY)
Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in two phase III clinical trials for the treatment of non-small cell lung cancer. The company is also developing PX-866, a small molecule that is in phase II trials for various cancer indications. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine; and ONT-701, a pan-inhibitor of the B-cell lymphoma-2 family of anti-apoptotic proteins. The company operates primarily in the United States and Canada. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.
Advisors' Opinion:- [By WWW.DAILYFINANCE.COM]
D Dipasupil/FilmMagicJustin Bieber's Someday perfume. Plenty of stocks go up and down in any given week. The gainers inspire us to keep investing. The decliners keep greed in check while reminding us about the risks of the equity markets. Let's go over some of last week's best and worst performers. China Finance Online (JRJC) -- Up 131 percent last week The market's biggest winner last week was China Finance Online, more than doubling after introducing a new trading platform. The Beijing-based financial website operator announced that the new offering was the country's first integrated, Web-based securities trading service platform. At least one noted worrywart disputed the claim. Citron Research -- a popular publisher of bearish reports on stocks -- tweeted that sloppy reporting and a misleading headline were making it seem as if no other online trading platform existed in the world's most populous nation. The bulls won out. Shares of China Finance Online closed sharply higher in each of last week's five trading days. TrueCar (TRUE) -- Up 33 percent last week Closer to home, another online platform moved nicely higher after striking a deal with Chrysler and auto insurer GEICO (BRK-A). TrueCar operates a negotiation-free car buying and selling platform. It launched a platform that could shake up the insurance industry, where roughly 3 million cars are totaled each year. Insurers have typically just written a settlement check and provided a rental car voucher to cover the incident, but TrueCar's new plan would work with launch partners GEICO and Chrysler -- and other members of its insurance affinity partners in the future -- to work with the insured to directly replace the vehicle. TrueCar went public at $9 just three months ago. The stock has been revving higher, going on to more than double in its brief time on the market. American Eagle Outfitters (AEO) -- Up 26 percent last week Shares of American Eagle Outfitters moved higher after it posted b
- [By Roberto Pedone]
One under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Oncothyreon (ONTY), which develops and markets synthetic vaccines and small molecules that treat cancer patients. This stock hasn't done much so far in 2013, with shares down modestly by 3.9%.
If you take a look at the chart for Oncothyreon, you'll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last month and change, with shares moving between $1.63 on the downside and $1.95 on the upside. Shares of ONTY have been finding some buying interest of late right above its 50-day moving average of $1.73 a share. This stock is now starting to push within range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern.
Traders should now look for long-biased trades in ONTY if it manages to break out above some near-term overhead resistance levels at $1.93 to $1.95 a share and then once it takes out more resistance at $1.98 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 689,364 shares. If that breakout triggers soon, then ONTY will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $2.12 a share to $2.70 a share.
Traders can look to buy ONTY off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $1.73 a share or around more support at $1.63 a share. One can also buy ONTY off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Ant贸nio Costa]
Oncothyreon Inc (NASDAQ: ONTY) is firming just above key support at $1.78 and a triangle has taken shape over the last few weeks. The stock is starting to show signs of accumulation with high upside days and low downside days. This stock is poised for a move and I suspect that it will explode to the upside. In addition, Inside trading has been very active over the last month. They are buying now after pausing years.
Best Warren Buffett Companies To Own In Right Now: ProShares Ultra Dow30 (DDM)
ProShares Ultra Dow30 (the Fund) seeks daily investment results that correspond to twice (200%) the daily performance of the Dow Jones Industrial Average (DJIA). The DJIA is a price-weighted index maintained by editors of The Wall Street Journal. The Index includes 30 large-cap, blue-chip United States stocks, excluding utility and transportation companies. Components are selected through a discretionary process with no predetermined criteria except that components should be established United States companies. The DJIA is not limited to traditionally defined industrial stocks, instead, the Index serves as a measure of the entire United States market, covering such diverse industries as financial services, technology, retail, entertainment and consumer goods. The Fund takes positions in securities and/or financial instruments that, in combination, should have similar daily return characteristics as 200% of the daily return of the Index. Its investment advisor is ProShare Advisors LLC. Advisors' Opinion:- [By Victor Selva]
In stock valuation models, dividend discount models (DDM) define cash flow as the dividends to be received by the shareholders. Extending the period indefinitely, the fundamental value of the stock is the present value of an infinite stream of dividends according to John Burr Williams.
No comments:
Post a Comment